Vir Biotechnology, Inc. Operating Expenses
Vir Biotechnology, Inc. (VIR) reported Operating Expenses of $157.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-11-04
- Vir Biotechnology, Inc. operating expenses for the quarter ending 2021-09-30 was $157.00M, a 75.34% increase year-over-year.
- Vir Biotechnology, Inc. operating expenses for the quarter ending 2021-06-30 was $116.05M, a 20.84% increase year-over-year.
- Vir Biotechnology, Inc. operating expenses for the quarter ending 2021-03-31 was $160.61M, a 106.90% increase year-over-year.
- Vir Biotechnology, Inc. operating expenses for the quarter ending 2020-12-31 was $110.14M, a 70.13% increase year-over-year.
- Vir Biotechnology, Inc. operating expenses for fiscal 2020 was $373.35M, a 100.65% increase from fiscal 2019.
- Vir Biotechnology, Inc. operating expenses for fiscal 2019 was $186.07M, a 43.84% increase from fiscal 2018.
- Vir Biotechnology, Inc. operating expenses for fiscal 2018 was $129.36M, a 53.63% increase from fiscal 2017.
- Vir Biotechnology, Inc. operating expenses for fiscal 2017 was $84.20M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2021-09-30 | $157.00M 10-Q · filed 2021-11-04 | $273.05M derived: sum of 2 quarters · filed 2021-11-04 | $433.67M 10-Q · filed 2021-11-04 | $543.80M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $116.05M 10-Q · filed 2021-08-05 | $276.67M 10-Q · filed 2021-08-05 | $386.80M derived: sum of 3 quarters · filed 2021-08-05 | $476.34M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-03-31 | $160.61M 10-Q · filed 2021-05-06 | $270.75M derived: sum of 2 quarters · filed 2021-05-06 | $360.29M derived: sum of 3 quarters · filed 2021-11-04 | $456.33M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-12-31 | $110.14M 10-K · filed 2021-02-25 | $199.68M derived: sum of 2 quarters · filed 2021-11-04 | $295.72M derived: sum of 3 quarters · filed 2021-11-04 | $373.35M 10-K · filed 2021-02-25 |
| 2020-09-30 | $89.54M 10-Q · filed 2021-11-04 | $185.58M derived: sum of 2 quarters · filed 2021-11-04 | $263.21M 10-Q · filed 2021-11-04 | $327.95M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $96.04M 10-Q · filed 2021-08-05 | $173.67M 10-Q · filed 2021-08-05 | $238.41M derived: sum of 3 quarters · filed 2021-08-05 | $287.49M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $77.63M 10-Q · filed 2021-05-06 | $142.37M derived: sum of 2 quarters · filed 2021-05-06 | $191.45M derived: sum of 3 quarters · filed 2021-05-06 | $229.27M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $64.74M 10-K · filed 2021-02-25 | $113.82M derived: sum of 2 quarters · filed 2021-02-25 | $151.64M derived: sum of 3 quarters · filed 2021-02-25 | $186.07M 10-K · filed 2021-02-25 |
| 2019-09-30 | $49.08M 10-K · filed 2021-02-25 | $86.90M derived: sum of 2 quarters · filed 2021-02-25 | $121.33M 10-Q · filed 2020-11-10 | $151.25M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $37.82M 10-K · filed 2021-02-25 | $72.25M 10-Q · filed 2020-08-11 | $102.17M derived: sum of 3 quarters · filed 2021-02-25 | $139.40M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $34.43M 10-K · filed 2021-02-25 | $64.35M derived: sum of 2 quarters · filed 2021-02-25 | $101.58M derived: sum of 3 quarters · filed 2021-02-25 | $128.80M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $29.92M 10-K · filed 2020-03-26 | $67.15M derived: sum of 2 quarters · filed 2020-03-26 | $94.37M derived: sum of 3 quarters · filed 2020-03-26 | $129.36M 10-K · filed 2021-02-25 |
| 2018-09-30 | $37.23M 10-K · filed 2020-03-26 | $64.45M derived: sum of 2 quarters · filed 2020-03-26 | $99.44M 10-Q · filed 2019-11-19 | |
| 2018-06-30 | $27.22M 10-K · filed 2020-03-26 | $62.21M derived: sum of 2 quarters · filed 2020-03-26 | ||
| 2018-03-31 | $34.99M 10-K · filed 2020-03-26 | |||
| 2017-12-31 | $84.20M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |